Subscription is FREE for qualified healthcare professionals in the US.
Subscribe or renew to PPM

All Pharmacological Articles

Inside abuse-deterrent formulations – and their potential impact on the opioid epidemic.
Despite its prevalent use, little evidence is shown to warrant the treatment of epidural steroid injections.
Despite evidence of benefitting OUD, MAT treatments are not made available to the vast majority of patients.
Cyproheptadine may be useful in treating chronic pain conditions such as sleep disorders, sexual dysfunction, refractory headaches, and more.
Sunascen Therapeutics have developed a line of non-habit forming pain relievers that are developed with the patient in mind.
Tanezumab is the first investigational humanized monoclonal immunoglobulin G2 antibody, preventing the binding of NGF to its receptors to block the pain response pathway.
What do patients really think about opioid vs non-opioid medications for chronic pain?
Alternative therapies for MSK pain, osteoarthritis, post-herpetic neuralgia, and peripheral neuropathy.
The author presents effective strategies to tapering your patients off of opioid therapy.
Chronic pain remains the same or gets better after stopping opioid treatment, according to a new study.
Medications which are commonly prescribed to people with dementia have been linked to an increase in harmful side-effects.
Agency continues its efforts to broaden access to generic versions of opioids formulated to deter abuse.
FDA will complete its review of REMOXY ER in August 2018.
In his new book, Medication Management of Chronic Pain: What You Need to Know, Gerald M. Aronoff, MD, DABPM, DABPN, medical director of Carolina Pain Associates in Charlotte, North Carolina, and former president of the American Academy of Pain Medicine, presents data to assist practitioners in their decision-making regarding medication management of complex chronic pain problems.
This article provides a sneak preview into the upcoming July/August 2018 issue of Practical Pain Management.
close X